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Abstract 
Controlled substances are among the most highly regulated and highly abused medications. The purpose of this study was to describe 
the classification systems for controlled substances in 23 countries and make comparisons. From this review, recommendations are 
provided for improving classification systems and their impact on medication use.  
 
 
Introduction 
Prescription and non-prescription drug abuse and overdose is 
a growing problem in the United States, and is referred to as 
a public epidemic by the Centers for Disease Control (CDC).  
Prescription drug overdose death rates have more than 
tripled since 19901.  It killed an estimated 37,485 people in 
2009 and is the cause of 100 deaths every day in the United 
Sates.  Every 19 minutes a person dies from a prescription 
pain killer overdose.  The CDC reports that today millions of 
Americans are addicted to opiates or prescription pain pills 
and “more than 12 million people reported using prescription 
painkillers non-medically in 2010-that is, using them without 
a prescription or for the feeling they cause.”2  
 
The economic costs of prescription drug abuse are 
substantial; drug and alcohol problems cost the United States 
an estimated $276 billion a year.3 Substance abuse results in 
higher healthcare expenses for injuries and illnesses; lower 
productivity and performance; an increase in workers’ 
compensation and disability claims.  In 2009, the misuse and 
abuse of prescription painkillers was responsible for more 
than 475,000 emergency department visits, which has nearly 
doubled in five years.4    
 
Methods 
The World Health Organization (WHO) website was used for 
identifying controlled substances regulations and the 
regulatory authorities responsible for medicines in each 
country. In addition, leaders in the pharmaceutical industry 
were contacted by email and mail in order to identify 
information about classification systems for controlled  
 
 
Corresponding Author: Lisa Dragic, PharmD Candidate May 
2016;  E-mail: tuc43657@temple.edu  
 
 
substances in countries world-wide. Information was 
gathered, sorted, and translated into English, when 
applicable. Information for 23 countries was identified. These 
countries were grouped into regions that had similar 
socioeconomic characteristics: North American, Western 
Europe, the Middle East, and Asia.  
 
Findings 
 
NORTH AMERICA 
 
United States 
In the United States, there are 5 categories of controlled 
substances. Schedule 1 drugs, substances, or chemicals are 
defined as drugs with no current medical use and a high 
potential for abuse. Such drugs include heroin, marijuana, 
and ecstasy, among many others. 
 
Schedule 2 drugs, substances, or chemicals are defined as 
drugs with a high potential for abuse, with use potentially 
leading to severe psychological or physical dependence. Such 
drugs include amphetamines, fentanyl, and oxycodone.  
Schedule 2 drugs allow no refills. A new prescription must be 
brought into the pharmacy each month. New to this category 
was the recent rescheduling of hydrocodone (Vicodin) which 
moved from schedule 4 to schedule 2.   
 
Schedule 3 drugs, substances, or chemicals are defined as 
drugs with a moderate to low potential for physical and 
psychological dependence. Some examples are Tylenol with 
Codeine and Buprenorphine.  
 
Schedule 4 drugs are defined as drugs with a low potential for 
abuse and a low risk of dependence. Some examples include 
Xanax (Alprazolam), Soma (Carisoprodol), and Valium 
(Diazepam). 
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Schedule 5 drugs are defined as drugs with lower potential 
for abuse than schedule 4 and consist of preparations 
containing limited quantities of certain narcotics. Some drugs 
include, Lomotil (Diphenoxylate and Atropine) and Phenergan 
with Codeine (Promethazine with Codeine). 
 
Schedule 3-5 drugs are allowed up to 5 refills and the 
prescription expires in 6 months.  
 
Canada 
In Canada, drugs and associated substances are regulated 
under the Controlled Drugs and Substances Act (CDSA).  
There are 8 categories listed as Schedules I to VIIi.  Schedule I 
includes the drugs that are commonly thought of as the most 
“dangerous”, e.g., cocaine and methamphetamine. 
Schedule II lists cannabis and its derivatives, while Schedule III 
includes amphetamines and lysergic acid diethylamide (LSD) 
and schedule IV includes barbiturates.  
 
The Canadian Alcohol and Drug Use Monitoring Survey 
(CADUMS) is an on-going survey that includes Canadians aged 
15 years or older using illicit drugs and alcohol.  Prescription 
opioids are included in Schedule I, and a recent analysis of 
2009 CADUMS data revealed that 4.8% of Canadians aged 15 
and older reported non-medical prescription opioid use 
during the past year; 0.4% of Canadians aged 15 and older 
reported the use of pain relievers to get high during the 
previous 12 months.6  
From 2005–2006 to 2010–2011, there was an almost 250% 
increase in the number of emergency room (ER) visits in 
Ontario related to narcotics withdrawal, overdose, 
intoxication, psychosis, harmful use and other related 
diagnoses.7 Rates of ER visits for opioid-related mental and 
behavioral disorders also increased in Ontario between 2008-
2009 and 2010-2011.8 Table I depicts ER visits in Ontario by 
region. 
Table I: ER visits in Ontario by region 
 
While there is no nation-level data on opioid-related 
mortality rate in Canada, provincial data is available from 
three jurisdictions: Ontario, Alberta, and British Columbia.  In 
Ontario the Office of the Chief Coroner reported that opiod-
related deaths doubled from 1991 to 2004.  Another recent 
study reported that there were 3,271 opioid-related deaths 
that occurred between 1991 to 2004.  In Alberta, deaths 
attributable to poisoning from narcotics or psychodysleptics 
(i.e. hallucinogenic drugs) accounted for the second-highest 
prescription drug-related death rate (3.9 per 100,000) 
between 2003 to 2006.9  The rate of prescription opioid-
related overdose deaths in one region of British Columbia 
was similar to the number of residents killed in motor-vehicle 
accidents involving alcohol (2-3 per 100,000 persons) in any 
given year.10  Between 2005 and 2009, there were 815 deaths 
related to fentanyl, hydromorphone, morphine, and 
oxycodone in British Columbia.11 
In 2010-2011, 1.5% of Canadian students in grades 6 to 12 
reported past-year use of tranquilizers to get high and for 
non-medical purposes; 2.5% reported such use of sleeping 
medicine.12 Among First Nations individuals aged 18 and 
older living on-reservations in northern First Nations 
communities across Canada, 5.7% reported past-year use of 
sedatives or sleeping pills without a prescription in 2008-
2010.13 In 2010-11 2.2% of Canadian students in grades 6-12 
reported the past year use of prescription stimulants for 
recreational use and not for medical use.12  There is little data 
on morbidity and mortality in Canada due to stimulant 
misuse. 
WESTERN EUROPE 
Western European countries are part of European Monitoring 
Centre for Drugs and Drug Addictions (EMCDDA).  The 
following information was provided by the EMCDDA for by 
each country and drugscience.org.uk, which is an 
independent scientific committee on drugs. 
 
Norway 
Until recently there was no separate set of laws pertaining 
only to drugs in Norway.  The King was empowered to 
determine what substances were narcotic drugs.  Then The 
King empowered the Director of Health who made a detailed 
list of narcotics.  On February 14, 2013 new Regulations 
relating to Narcotics entered into force.  Ten groups of 
substances, seven of them describing cannabinoids, are 
included on the list of controlled substances.14     
 
SIRUS and Statistics Norway formed a collaboration to 
annually survey the national population to measure the use 
of tobacco/moist snuff, alcohol, drugs, and medicines.  The 
findings on drug use reported use during the last 30 days.   A 
Region 2008–2009 ER Visits 2010–2011 ER Visits 
All of Ontario 2.6 for every 10,000 people 
3.7 for every 10,000 
people 
Northern Ontario 
only 
9.2 for every 10,000 
people 
22.9 for every 10,000 
people 
First Nations 12.1 for every 10,000 people 
55 for every 10,000 
people 
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proportion of 9 per cent reported having used an illegal 
morphine substance during the past month, 33 per cent 
cannabis and 42 per cent benzodiazepines. Half of those who 
reported using benzodiazepines had been prescribed the 
drug by a doctor. Sixteen per cent reported using 
stimulants.14 Norway ranks high on the European statistics for 
overdoses.  As shown in Figure 1, heroin, other opioids, and 
methadone were the leading causes of drug-related deaths in 
2011 in Norway.   
 
Figure 1: Drug-related deaths in 2011 broken down by 
substance in Norway 
 
Source: SIRUS and Statistics Norway 
 
Denmark 
The main Danish law regulating narcotic drugs is the 
Euphoraints Act of 1955.  Substances that are defined as 
Euphorants under the Act are included in 5 lists in an annex 
to an Executive Order.  The annex to the Executive Order no. 
749 of 1 July 2008 on euphoriant substances lists 5 schedules, 
A, B, C, D and E.  Schedule A includes substances such as: 
cannabis, heroin, prepared opium, etc. Schedule B includes 
substances such as: cocaine, MDMA, amphetamines, and 
methadone. Schedule C includes substances such as codeine, 
while schedule D contains barbiturates and schedule E 
contains tranquillisers.15 
 
Sweden 
The main Swedish law regulating narcotic drugs is the 
Narcotic Drugs Punishments Act (1968:64).  The term 
"narcotic drugs" is defined in Section 8 of the Narcotic Drugs 
Punishments Act (1968:64). Under this provision, narcotic 
drugs are considered to be medicines or substances 
hazardous to health with addictive properties, or inducing a 
state of euphoria, which the Government has declared to be 
'narcotic drugs' within the meaning of the Act. In Sweden, no 
distinction is made between narcotic preparations as such 
and psychotropic substances.15 
 
Belgium 
The list of controlled substances was established by Royal 
Decree of 31 December 1930 regarding soporific and narcotic 
drugs and by the Royal Decree of 22 January 1998 regarding 
certain psychotropic substances.  They are both constantly 
revised in order to stay up to date with new substances.  
Soporific and narcotic substances include opium, heroin, 
cocaine, morphine, methadone, cannabis and cannabis resin. 
Psychotropic substances include amphetamines, 
hallucinogens, pipradol and MDMA. A directive of April 1998, 
replaced by that of 16 May 2003, instructed judicial 
authorities to make a distinction between personal 
consumption of cannabis derivatives and other drugs, based 
on the health risks the drug use provoke. This was embedded 
in the change of law in May 2003 with separate penalties 
specified for non-problematic use of small amounts of 
cannabis products.15 
Luxembourg 
Three Grand Ducal Decrees of March 1974 cover narcotic 
drugs (such as cannabis, cocaine, heroin, methadone), 
psychotropic substances (LSD, MDMA) and toxic substances 
(amphetamine) respectively. 
(http://www.emcdda.europa.eu/html.cfm/index146601EN.ht
ml) 
 
Slovenia 
Controlled substances are classified into three groups: 
• Group I: plants and substances which are very 
dangerous to human health due to the severe 
consequences which can result from their abuse and 
which are not used in medicine (heroin, cocaine, 
opium poppy concentrate, cannabis/THC, PCP, 
MDMA, MDA, MDE, khat, mescaline, psilocybin, etc); 
• Group II: plants and substances considered highly 
dangerous, due to the severe consequences which 
can result from their abuse, and which can be used 
in medicine (cocaine, amphetamine, 
methamphetamine, opium, morphine, codeine, 
methadone, buprenorphine, etc.); 
• Group III: plants and substances of medium danger, 
due to the consequences which can result from their 
abuse, and which can be used in medicine (mostly 
barbiturate and non-barbiturate hypnotics and anti-
epileptics, benzodiazepine anxyolitics and hypnotics, 
and stimulants and anorectics /arylalkylamin and 
others/ such as: GHB and 2 C-B).15 
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Netherlands 
The 'main' drug law in the Netherlands is the Opium Act.  
Illegal substances are annexed to the Opium Act and divided 
in two schedules: substances presenting unacceptable risks 
and other substances:  Schedule I, 'drugs presenting 
unacceptable risks' , is subdivided in a, b, and c: 
• Ia: including among others opiates, cocaine, 
cannabis oil; 
• Ib: Codeine; 
• Ic: amphetamines and LSD. 
Schedule II is subdivided in a and b: 
• IIa: includes tranquillizers and barbiturates; 
• IIb: includes cannabis (without the qualification of 
unacceptability). 
 
The division in schedules has a real impact in the prosecution 
of illegal offences: penalties for offences with regard 
to Schedule II are considerably lower than those 
for Schedules I.15 
Germany 
The Germany Narcotic Act divides the controlled substances 
into Schedule I, II, and III: 
• Schedule I includes: "non-marketable narcotics"; 
these are illicit narcotics without current evidence-
based medical benefit, e.g. heroin and all Ecstasy-
type drugs. 
• Schedule II includes: "licit narcotic drugs, but not 
available as such on special prescription", e.g. 
narcotics which are used commercially for the 
manufacture of other products, particularly 
pharmaceuticals. These include, inter alia, delta-9-
tetrahydrocannabinol (THC) and dexamphetamine. 
• Schedule III includes: "marketable narcotic drugs 
available on special prescription", these are all 
narcotic drugs which may be prescribed by 
physicians, dental surgeons and veterinary surgeons 
for medical purposes (e.g. opium, morphine and 
methadone).16 
 
France 
Controlled substances are annexed to the Decree Law of 22 
February 1990, included in 4 lists: 
• List I: narcotic substances such as heroin, cocaine, 
cannabis, methadone, opium, etc.; 
• List II: substances like codeine, propiram, etc.; (Lists I 
and II correspond to those in the Single Convention 
of 1961) 
• List III: psychotropic substances of the 1971 Vienna 
Convention, such as: amphetamines, ecstasy 
(MDMA), LSD, etc; and 
• List IV: substances not controlled at the international 
level, such as: MBDB, 4-MTA, Ketamine, Nabilone, 
THC, etc. 
Precursors are listed and controlled under Decree Law n°96-
1060 of 5 December 1996.15 
 
Spain 
Under Spanish law there is not a specific definition of narcotic 
drugs or psychotropic substances, nor specific lists or 
schedules where the controlled drugs are classified. 
Therefore, judicial authorities refer directly - for the 
interpretation and application of the laws in accordance with 
article 2 of law 17/1967 and art. 1 of the Royal Decree 
2829/1977 - to the schedules of narcotics drugs and 
psychotropic substances included, respectively, in the 1961 
Single Convention on Narcotics Drugs and in the 1971 
Convention on Psychotropic Substances.15 
Portugal 
Controlled substances are annexed to the main drug Decree 
Law 15/93 included in 6 schedules, regularly updated by 
decree laws.  
• List 1 is divided into opiates; coca derivatives; 
Cannabis and derivatives.  
• List 2 is divided into Hallucinogenic; Amphetamines; 
Barbiturates.  
• List 3 contains preparations with controlled 
substances. 
• List 4 tranquillizers and analgesics.  
• Lists 5 and 6 contain precursors. 
The difference between lists has an impact on the 
punishment of drug related crimes.15 
 
Italy 
Controlled substances in Italy are classified in six lists 
attached to the Decree 4 March 1992 and amendments. 
• List I includes opiates and cocaine derivatives 
• List II cannabis 
• List III highly addictive barbiturates 
• List IV medical substances 
• List V special preparation containing drugs 
• List VI stimulants.15 
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Austria 
All controlled substances as defined by law are listed in eight 
schedules introduced by three decrees covering respectively: 
• narcotics (5 schedules); 
• psychotropic substances (1 schedule); 
• precursors (2 schedules). 
Any substance to be officially designated as a controlled drug 
must be included in one of the relevant decrees. Following 
this classification, and with regard to possible sanctions and 
penalties, a distinction is made according to the nature of the 
substance when prosecuting drugs offences.15 
 
United Kingdoms 
The Misuse of Drugs Act divides drugs into 5 Schedules and 
controlled substances into 3 classes (A, B, C): 
• Drugs in Schedule 1 have no acknowledged 
therapeutic use and are the most tightly regulated, 
while those in the other four Schedules have medical 
uses and are subject to lesser regulation with those 
in Schedule 4 and 5 being least regulated. The fifth 
Schedule applies to low concentration preparations 
of the drugs which are not for injection. 
• Controlled drugs are included in Schedule 2 broken 
down into 3 classes: 
o Class A being the most dangerous, such as 
heroin. Methadone 
o Class B, such as amphetamines  
o Class C drugs, such as cannabis and 
temazepam 
Hungary 
The list of controlled substances is found in three major laws: 
• 4/1980. (VI. 24.) Decree of the Minister of Health 
and the Minister of Internal Affairs on the 
production, trafficking, import, export, storage and 
use of psychotropic substances (including national 
psychotropic lists). Annex I. lists psychotropic 
substances that can only be used for scientific 
purposes; Annexes II.-III.-IV. list substances that can 
be used for medicinal purposes. 
• 1/1968. (V. 12.) Decree of the Minister of Internal 
Affairs and the Minister of Health on the production, 
trafficking, import, export, storage and use of 
narcotic substances (including national lists of 
narcotic drugs). Annex I lists the narcotic substances 
contained in the UN Single Convention on Narcotic 
Drugs (New York, 1961); Annex II lists those 
substances that are not listed in the Convention but 
are regarded controlled substances in Hungary; 
Annex III Lists licit narcotic substances and medicines 
containing narcotic drugs.  
 
• Government Decree No. 272/2001.(XII.21.) on 
precursors (including the list of precursors). 
• Finally, under s.282/B, an adult encouraging a minor 
to use a substance that has a narcotic effect but is 
not classified as a narcotic drug is punishable by up 
to 3 years’ imprisonment. 
 
Poland 
The Act of 29 July 2005 on counteracting drug addiction 
includes two appendices. The first one covers the list of 
narcotic substances that are divided into following four 
groups: I-N, II-N, III-N and IV-N. The second one covers the list 
of psychotropic substances that are divided into following 
groups: I-P, II-P, III-P and IV-P. All the lists and relevant groups 
follow the pattern used in international agreements. The 
previously attached list of precursors has been removed 
following accession of Poland to the EU. Currently the Act 
refers directly to the Regulation 273/2004/EC as regards 
precursors. 
Finland 
In Finland there are ten classes that classify controlled 
substances.  
Narcotics                                           
I    heroin, cannabis, methadone, morphine, etc.    
II    propiram, codeine, etc.                        
III   preparations containing drugs                       
IV   drugs in Class I with no medical uses  
 
Psychotropic substances                                           
I   MDA, LSD, MDMA, etc.                      
II   amphetamines, THC, etc.                        
III    barbiturates                                     
IV   benzodiazepines etc.  
 
Precursors                                           
I    ephedrine, lysergic acid                                 
II    acetone, piperidine.  
 
MIDDLE EAST 
 
Israel 
In Israel there are two major medication categories, those 
that can be sold in an authorized store, the authorization not 
being what store but that the medication must be placed at a 
level where minors cannot reach them, and the second 
category pharmacy only medications. 
 
The former are GSL (General Sales List medications) and they 
are sold in small packs, and generally at higher prices than in 
a pharmacy and are very restricted in number. Examples are 
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Paracetamol (Acetaminophen), some nose drops and 
diclofenac gel. The sales of these are very small and 99% of 
the population does not buy them.  
 
The latter groups are sold only in pharmacies and only a 
pharmacist can hand out medications. These medications 
sold in the pharmacy fall into three categories: 
 
• 1 OTC medications 
• 2 Prescription only medicines 
• 3 Regular medications with reasonable safety 
profiles (labelled P) 
• Ii Separanda (meaning to be kept apart from other 
medicines( to reduce mistakes the pharmacist is 
thus  reminded by the place of the medicine that it 
requires greater attention when selling (Labelled S) 
• Iii Toxica – those medications with a small 
therapeutic window requiring extra special attention 
with dosing and advice (E.G. Digoxin) (Labelled T) 
• The Toxica category is also divided into Narcotic 
(additionally labelled This preparation can cause 
dependence) and non- narcotic categories 
• A prescription renewal for P Medications is required 
each month and  the patient may receive three such 
prescriptions when visiting the physician 
• A prescription for S and non- narcotic T Medications 
is required each month and the patient may receive 
three such prescriptions when visiting the physician.  
• A prescription for a narcotic can only be written for 
10 days unless the physician stipulates why the 
patient should receive more EG "Patient is not 
mobile enough to get the medications easily and has 
no home help". In this case they could receive one 
month's supply, but never above that amount 
without a new prescription. The full instructions 
must be written so the wording " as directed" is not 
acceptable. 
• The physician is encouraged by the 
pharmacist  (pending an incoming law) to write the 
disease or reason for prescribing the medication 
particularly if it is a narcotic. 
• All prescriptions must be written in Capital Letters or 
printed. 
• Electronic Rx are now quite common so new Rxs can 
be received without much problem for the patient 
and thus reducing the number of forgeries. 
 
Medicinal Marijuana is at present distributed on Rx by 
specialized physicians through specialized dispensaries. This is 
shortly to be changed to pharmacy only distribution for 
specially trained pharmacists. 
 
ASIA 
 
Australia 
Controlled substances are regulated under the Therapeutic 
Goods Administration Act (TGA).   The nine Schedules are 
published in the Standard for the Uniform Scheduling of 
Medicines and Poisons (SUSMP).17 
• Schedule 1 (S1)-Not currently in use  
• Schedule 2 (S2) - Pharmacy Medicines 
• Schedule 3 (S3) - Pharmacist Only Medicines 
• Schedule 4 (S4) - Prescription Only Medicines OR 
Prescription Animal Remedy 
• Schedule 5 (S5)- Caution 
• Schedule 6 (S6)-Poison 
• Schedule 7 (S7)-Dangerous Poison 
• Schedule 8 (S8) - Controlled Drugs 
• Schedule 9 (S9)-Prohibited Substance 
 
New Zealand 
Controlled Drugs are classified under the Misuse of Drugs Act 
1975 into 4 Classes.  Drugs that have very high risk and 
addiction potential are listed in Class A, and high risk in Class 
B, and moderate risk in Class C.  Precursors are included in 
the fourth Class. 
• Class A classification is limited to the most serious 
drugs requiring severe restrictions.  The category has 
been described by Dr. Bob Boyd, Ministry of Health 
Chief Advisor, as “reserved for substances that one 
doesn’t want to see in the country at all, and to 
presume that somebody in possession is either going 
to harm themselves or somebody else quite 
severely.” 19  Currently thirty-seven substances are 
listed as Class A in the First Schedule to the Act; 
these include cocaine, heroin, LSD, phencyclidine 
(PCP), thalidomide, amphetamine substances (MDA, 
MMDA) and most recently methamphetamine. 18 
• Class B drugs, listed in the Second Schedule to the 
Act, are divided into three parts.  Class B Part 1 (B1) 
drugs are generally processed substances, including 
opiates with both therapeutic and abuse potential 
(e.g. morphine), as well as cannabis preparations 
(resin and oil as refined and concentrated forms of 
cannabis have a higher potency than the natural 
plant.  Class B Part 2 drugs are mainly stimulants 
with less dependence potential than B1 substances; 
these include amphetamine, ecstasy (MDMA) and 
methylphenidate (Ritalin). Class B Part 3 includes 
methadone, pethidine and other drugs commonly 
used for medical purposes. Part 3 may also list drugs 
not yet used in New Zealand, but classified 
internationally.18 
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• There are seven categories of Class C drugs listed in 
the Third Schedule.  
o Class C Part 1 substances commonly used 
illicitly rather than medically, including 
cannabis leaf, fruit and seed, and coca leaf. 
o Class C Part 2 substances that can be 
prescribed for therapeutic purposes but have a 
moderate abuse potential. The list includes 
codeine powder, codeine linctus and syrup.  
o Class C Part 3 partially exempted drugs, 
including pholcodine that have less 
dependence potential than C2 substances.  
o Class C Part 4 includes barbiturates with 
medical uses. 
o Class C Part 5 substances that have medical 
uses and less dependence and abuse potential 
than C4. These include phenobarbital, 
barbiturates in combination, diazepam 
(Valium) and nitrazepam (Mogadon).  
o Class C Part 6 exempted drugs such as codeine 
and paracetamol.  
o Class C Part 7 controlled drug analogues 
(substances that have similar structures to 
controlled drugs); including so-called ‘designer 
drugs’ such as amphetamine analogues (MDEA) 
and pethidine analogues.18 
• Schedule 4 lists precursor substances commonly 
used as ingredients in the manufacture of illicit 
substances. Part 1 of the schedule includes 
ephedrine and pseudoephedrine used in the 
manufacture of methamphetamine. Part 2 includes 
sulphuric acid and ethyl ether.18 
 
Japan 
Drug categories include those that are highly poisonous, 
which have serious adverse reactions and which are addictive 
or habit forming. They are classified as follows in related laws 
such as the Pharmaceutical Affairs Law (the Law) or the 
Stimulants Control Law20 
1. Poisonous substances (Article 44 of the Law). 
2. Deleterious substances (Article 44 of the Law). 
3. Drugs requiring a prescription (Article 49 of the Law). 
4. Habit-forming drugs (Article 50 of the Law). 
5. Drugs for specially designated diseases (Article 67- of 
the Law). 
6. Drugs manufactured in pharmacies (Article 22 of the 
Pharmaceutical Affairs Law) 
7. Narcotics (Narcotics and Psychotropics Control Law). 
8. Psychotropic drugs (Narcotics and Psychotropics 
Control Law). 
9. Opium and powdered opium (Opium Law). 
10. Cannabis (Cannabis Control Law). 
11. Stimulants (Stimulant Control Law). 
12. Clinical study drugs (investigational products) (GCP). 
13. Investigational products for post-marketing clinical 
trials (GCP). 
14. Biological products (Article 2, Paragraph 9 of the 
Law) 
15. Specified biological products (Article2, Paragraph 10 
of the Law)20 
 
Summary of Findings 
From this preliminary collection of 23 countries, it was 
learned that the range of controlled substance schedules 
goes from 2 to 15. We do not know which system seems to 
function the best, which is research that should be conducted 
next. Whenever there are many different methods to solve a 
universal problem it means that there is no one best way. It is 
interesting how many different methods there are for a 
classification system for one universal problem. The European 
Country with the most liberal drug law is Portugal, which has 
6 classification systems.21 In 2001, it was the first European 
country to officially abolish all criminal penalties for personal 
possession of drugs.21 The question everyone is wondering is 
could such a liberal system work? Just after 5 years after the 
decriminalization illegal drug use among teens in Portugal 
declined and rates of new HIV infections caused by sharing 
dirty needles dropped, while the number of people seeking 
treatment for drug addiction more than doubled.21 Following 
decriminalization, Portugal had the lowest rate of lifetime 
marijuana use in people over 15 in the E.U.: 10%. The most 
comparable figure in America is in people over 12: 39.8%.21 
Proportionally, more Americans have used cocaine than 
Portuguese have used marijuana.21 
 
The U.S. has long championed a hardline drug policy, 
supporting only international agreements that enforce drug 
prohibition and imposing on its citizens some of the world's 
harshest penalties for drug possession and sales.21 Even with 
the hardline drug policy, America has the highest rates of 
cocaine and marijuana use in the world.21 While most of the 
E.U. (including Holland) has more liberal drug laws than the 
U.S., it also has less drug use.21 
 
Recommendations 
The solution of this problem is the creation of a system that 
provides hurdles to abusers, but does not add additional 
barriers to the receipt of scheduled drugs for legitimate 
users. It was found that there are numerous ways to control 
abusable substances and it is not clear what the best system 
is. What is known is that each day 46 people die in this 
country after overdosing on prescription painkillers.22 Is the 
American system truly working? In just the past year 
Tramadol has moved to be a controlled substance and all 
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hydrocodone products are now narcotic substances. Are 
tighter regulations in the classification system working? Could 
the problem not be the system, but rather the doctors not 
cautiously prescribing these medications? Prescription 
painkillers are meant for end-of-care life or for short term 
treatment. The problem may not be the system per say, but 
instead how America is prescribing these medications. The 
United States, with about 5 percent of the world’s 
population, is consuming 80 percent of the world’s entire 
oxycodone supply and 99 percent of the world’s hydrocodone 
supply.22 
 
Here lies the problem, with tighter regulations; the people 
who are in pain have to suffer because of this epidemic. Bob 
Twillman of the American Academy of Pain Management 
suggests that, “If prescription drug abuse is an epidemic, then 
I think chronic pain may be a pandemic, because the Institute 
of Medicine tells us that it affects over 100 million people in 
the United States.  So I think what we have to do is to find the 
kinds of solutions that really address both of these problems 
and don’t wind up giving us what’s essentially a zero sum 
game.”  
 
Maybe the key to success is addressing both of the problems. 
Many people in pain obtain their narcotic prescriptions from 
their primary care physicians. Often times, doctors don’t 
really evaluate the status of the patient.  Utilizing more pain 
scales and asking more detailed questions may lead to other 
questions and ultimately see that the patient maybe a drug 
seeker. If someone is battling chronic pain, that pain should 
be handled by a group of health care professionals at a pain 
specialist.  
 
Electronic health records would help tremendously between 
doctors and pharmacists. The pharmacist has limited access 
to records about the patient.  Thus, allowing the pharmacist 
to solely base judgment off of what the patient says. Many 
pharmacists are left to being mini “DEA agents.” Trying to 
crack the code and see if a prescription is legitimate. A 
system where health care providers could communicate more 
efficiently and easily would allow more questions to be 
answered. Doctors can check a patient database before 
writing any prescriptions. Pharmacists can check the 
databases to make sure patients haven’t been elsewhere. A 
team based approach would be more effective.  
 
All in all, more pain management training needs to be 
presented in both pharmacy and medical schools. This is a 
topic that is brushed upon, but needs to be addressed to the 
fullest extent. Health care professionals would then be better 
rounded and more knowledgeable in the area leading to 
better outcomes.  
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